Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5939353 | 0.94 | HSD11B1 (0.46) | HSD11B1HSD17B10NPC1UCHL1ALDH1A1 | |
| SCHEMBL5938430 | 0.94 | HSD11B1 (0.46) | HSD11B1HSD17B10NPC1UCHL1ALDH1A1 | |
| SCHEMBL23406491 | 0.91 | HSD11B1 (0.41) | HSD11B1HSD17B10 | |
| SCHEMBL23406490 | 0.91 | HSD11B1 (0.41) | HSD11B1HSD17B10 | |
| SCHEMBL5938275 | 0.91 | HSD11B1 (0.41) | HSD11B1HSD17B10 | |
| SCHEMBL15245630 | 0.90 | HSD11B1 (0.42) | HSD11B1HSD17B10NPC1UCHL1 | |
| SCHEMBL5940111 | 0.88 | NPC1 (0.46) | HSD11B1HSD17B10NPC1UCHL1ALDH1A1 | |
| SCHEMBL1691897 | 0.87 | HSD11B1 (0.40) | HSD11B1HSD17B10NPC1UCHL1 | |
| SCHEMBL1691937 | 0.87 | HSD11B1 (0.40) | HSD11B1HSD17B10NPC1UCHL1 | |
| SCHEMBL5939603 | 0.84 | CHRM2 (0.41) | HSD11B1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | DART MICHAEL J | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287290-A1 | Azabicyclic compounds are central nervous system active agents | ACHE, CHAT, CHRNA6 | HSD11B1 959/4885HSD17B10 1971/4885NPC1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.